CME and CFTC Clash Over On-Chain Perpetual Futures

The disagreement between the CME Group and the U.S. Commodity Futures Trading Commission (CFTC) revolves around the regulator's decision to allow blockchain-based perpetual future products, known as perps, which enable users to speculate on asset prices with leverage and no expiration date. The CME Group has filed a lawsuit against the CFTC, arguing that these products are harmful to its long-dated futures products and that the regulator's sudden embrace of them did not consider the ramifications. The CME claims that the CFTC is mislabeling perps as futures, which require an end date, and that the agency is misapplying the law. The lawsuit has sparked a highly politicized debate, with some voicing frustration and outrage over the CME's actions. The CFTC's reforming agenda has been met with resistance from the CME, which has a significant influence over commodities in the U.S. The CME's chairman, Terry Duffy, has stated that the definition of a swap is clear and that perps are, in fact, swaps, which come with obligations to maintain margin and register with the CFTC. The CFTC's decision to allow perps has been seen as a departure from its previous stance, and the agency's ability to enforce its emerging perps policy has been questioned. The dispute has significant implications for the U.S. approach to the rapidly growing perps market, with non-U.S. perps volume reportedly reaching $60 trillion in 2023. The CME's lawsuit argues that the CFTC's approval of perps will harm its business and that the regulator has not considered the potential consequences of its actions. The case is ongoing, with both sides awaiting federal court action. The outcome of the dispute will have significant influence on the future of perps in the U.S. and the role of the CFTC in regulating the market.